Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMP16-01 versus Xenical in obese adult men over 2 weeks
2016-001055-50Phase 2Completed
- Sponsor
- Empros Pharma
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EMP16, orlistat in obesity, type 2 diabetes mellitus (T2DM), sponsored by Empros Pharma. Started May 2016; status: completed.
02
Drugs
EMP16orlistat
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001055-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001055-50.